STOCK TITAN

Mangoceuticals Inc - MGRX STOCK NEWS

Welcome to our dedicated news page for Mangoceuticals (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mangoceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mangoceuticals's position in the market.

Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) launches a direct-to-clinics sales division, allowing doctors to prescribe MangoRx products from their offices. The company aims to increase recurring revenues and reduce customer acquisition costs by deploying a sales force to penetrate men’s health and wellness clinics across the US. The newly developed clinic prescribing system enables practitioners to prescribe MangoRx products, including the recently launched 'PRIME', by MangoRx, powered by Kyzatrex®️.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) offers San Francisco players and coaches a free one-year supply of its 'Mango' erectile dysfunction product following a Big Game loss. Fans can also get 3 free Mango pills with a special discount code 'SB58'. The product contains active ingredients from Cialis and Viagra, compounded with Oxytocin and L-Arginine in a Mango-flavored rapid dissolve tablet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.36%
Tags
none
-
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announces a promotion offering the losing team of the Big Game a free one-year supply of its Mango ED products. Fans can also get a special discount code equal to the game's point difference. The company's uniquely formulated Mango ED products are designed to help men tackle performance issues in the bedroom. MangoRx will also be the marquee sponsor for several Barstool Sports' week-long programming surrounding the Big Game in Las Vegas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
none
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) is offering 2 months of free ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ for the first 1,000 male subscribers interested in subscribing to the oral testosterone replacement protocol. The company is also providing discounted prices for a minimally invasive FDA approved at-home blood collection test kit through their nationwide lab partnership with Trybe Labs. Jacob Cohen, MangoRx’s Co-Founder and CEO, expressed excitement about the official PRIME launch and the one-time promotion for the first 1,000 interested subscribers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
fda approval
-
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announces its sponsorship of Barstool Sports' week-long programming schedule surrounding the Big Game in Las Vegas, featuring its FDA-approved oral Testosterone Replacement 'Prime' by MangoRx, powered by Kyzatrex. The company will be a Marquee Sponsor and will be featured across Barstool programming during the week of the Super Bowl, reaching an estimated number of over 7 million views and impressions. The partnership aims to showcase 'Prime' to the passionate fans of Barstool Sports and expand broad-based consumer access to this revolutionary therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
-
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $0.30 per share, with aggregate gross proceeds of $1,200,000 to the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.96%
Tags
offering
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) announces a marketing agreement with Marius Pharmaceuticals to launch KYZATREX, an FDA-approved oral Testosterone Replacement Therapy, under the program PRIME by MangoRx. KYZATREX is expected to be available on MangoRx's telemedicine platform starting January 31, 2024. The new therapy aims to address testosterone deficiency in men, with a focus on providing a convenient and effective treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
fda approval
-
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) is expanding its sales access across Latin America with the establishment of its subsidiary, MangoRx Mexico, aiming to tap into the Mexican market for men's health and wellness products, particularly its uniquely formulated hair growth product 'GROW' and erectile dysfunction (ED) drug 'Mango'. The company has engaged Diaz Reus International Law Firm for establishing its subsidiary presence in Mexico and is in the process of establishing manufacturing and distribution partnerships. The estimated annual market size in Mexico for ED pharmaceutical products is USD $216 million with approximately 24 million units sold annually and growing at a rate of 4% per year at an average sales price of USD $8.50 per unit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
-
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) announces partnership with TRYBE Labs to provide at-home blood collection services for its men's health and wellness products. The collaboration aims to expand product lines requiring blood tests and results reviewed by physicians, offering innovative, convenient, and minimally invasive solutions for male health and performance evaluation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.61%
Tags
none
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ:MGRX) announces the addition of 'Grow,' a hair growth treatment, to its men's health product line. Combining Minoxidil, Finasteride, Vitamin D3, and Biotin in chewable tablets, the product is available for delivery by prescription through MangoRx's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
Mangoceuticals Inc

Nasdaq:MGRX

MGRX Rankings

MGRX Stock Data

4.95M
9.49M
57.37%
0.8%
1.75%
Pharmacies and Drug Stores
Retail Trade
Link
United States
Dallas